These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 30102964)

  • 1. A twenty-two-year experience with Hymenoptera venom immunotherapy in a US pediatric tertiary care center 1996-2018.
    Albuhairi S; El Khoury K; Yee C; Schneider L; Rachid R
    Ann Allergy Asthma Immunol; 2018 Dec; 121(6):722-728.e1. PubMed ID: 30102964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exclusive Bee Venom Allergy: Risk Factors and Outcome of Immunotherapy.
    Rosman Y; Nashef F; Cohen-Engler A; Meir-Shafrir K; Lachover-Roth I; Confino-Cohen R
    Int Arch Allergy Immunol; 2019; 180(2):128-134. PubMed ID: 31216540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Venom immunotherapy for preventing allergic reactions to insect stings.
    Boyle RJ; Elremeli M; Hockenhull J; Cherry MG; Bulsara MK; Daniels M; Oude Elberink JN
    Cochrane Database Syst Rev; 2012 Oct; 10(10):CD008838. PubMed ID: 23076950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term follow-up of re-sting reactions in children with moderate to severe venom hypersensitivity.
    Ertoy Karagol HI; Bakirtas A; Yilmaz O; Topal E; Arga M; Demirsoy MS; Turktas I
    Eur J Pediatr; 2015 Jul; 174(7):891-6. PubMed ID: 25563216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Three days rush venom immunotherapy in bee allergy: safe, inexpensive and instantaneously effective.
    Goldberg A; Yogev A; Confino-Cohen R
    Int Arch Allergy Immunol; 2011; 156(1):90-8. PubMed ID: 21447964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maintenance venom immunotherapy administered at 3-month intervals is both safe and efficacious.
    Goldberg A; Confino-Cohen R
    J Allergy Clin Immunol; 2001 May; 107(5):902-6. PubMed ID: 11344360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and Efficacy of a Progressively Prolonged Maintenance Interval of Venom Immunotherapy.
    Kontou-Fili K; Pitsios C; Kompoti E; Giannakopoulos D; Kouridakis S
    Int Arch Allergy Immunol; 2018; 176(1):39-43. PubMed ID: 29649812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rush hymenoptera venom immunotherapy is efficacious and safe.
    Pasaoglu G; Sin BA; Misirligil Z
    J Investig Allergol Clin Immunol; 2006; 16(4):232-8. PubMed ID: 16889280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunoblot studies in allergic patients to hymenoptera venom before and during immunotherapy.
    Pereira Santos MC; Pedro E; Spínola Santos A; Branco Ferreira M; Palma Carlos ML; Palma Carlos AG
    Eur Ann Allergy Clin Immunol; 2005 Sep; 37(7):273-8. PubMed ID: 16285233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bee-venom allergy in children: long-term predictive value of standardized challenge tests.
    Schuetze GE; Forster J; Hauk PJ; Friedl K; Kuehr J
    Pediatr Allergy Immunol; 2002 Feb; 13(1):18-23. PubMed ID: 12000494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of hymenoptera venom immunotherapy.
    Kayikci H; Bostan OC; Tuncay G; Cihanbeylerden M; Damadoglu E; Karakaya G; Kalyoncu AF
    Allergy Asthma Proc; 2024 Jul; 45(4):268-275. PubMed ID: 38982604
    [No Abstract]   [Full Text] [Related]  

  • 12. Subcutaneous venom immunotherapy in children: Efficacy and safety.
    Gür Çetinkaya P; Esenboğa S; Uysal Soyer Ö; Tuncer A; Şekerel BE; Şahiner ÜM
    Ann Allergy Asthma Immunol; 2018 Apr; 120(4):424-428. PubMed ID: 29625665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discontinuing venom immunotherapy.
    Golden DB
    Curr Opin Allergy Clin Immunol; 2001 Aug; 1(4):353-6. PubMed ID: 11964712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natural history of Hymenoptera venom allergy in children not treated with immunotherapy.
    Lange J; Cichocka-Jarosz E; Marczak H; Krauze A; Tarczoń I; Świebocka E; Lis G; Brzyski P; Nowak-Węgrzyn A
    Ann Allergy Asthma Immunol; 2016 Mar; 116(3):225-9. PubMed ID: 26945496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention and treatment of hymenoptera venom allergy: guidelines for clinical practice.
    Bonifazi F; Jutel M; Biló BM; Birnbaum J; Muller U;
    Allergy; 2005 Dec; 60(12):1459-70. PubMed ID: 16266376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety profile of hymenoptera venom immunotherapy (VIT) in monosensitized patients: lack of new sensitization to nontreated insect venom.
    Spoerl D; Bircher AJ; Scherer K
    J Investig Allergol Clin Immunol; 2011; 21(1):22-7. PubMed ID: 21370719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy and biologicals for the treatment of allergy to Hymenoptera stings.
    Ridolo E; Pellicelli I; Kihlgren P; Nizi MC; Pucciarini F; Senna G; Incorvaia C
    Expert Opin Biol Ther; 2019 Sep; 19(9):919-925. PubMed ID: 31190572
    [No Abstract]   [Full Text] [Related]  

  • 18. Rush Venom Immunotherapy in Children.
    Confino-Cohen R; Rosman Y; Goldberg A
    J Allergy Clin Immunol Pract; 2017; 5(3):799-803. PubMed ID: 27914814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the Safety Profiles of 3 Different Hymenoptera Venom Immunotherapy Protocols: A Retrospective 2-Center Study of 143 Patients.
    Pospischil IM; Kagerer M; Cozzio A; Angelova-Fischer I; Guenova E; Ballmer-Weber B; Hoetzenecker W
    Int Arch Allergy Immunol; 2020; 181(10):783-789. PubMed ID: 32781451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deliberate bee sting challenge of patients receiving maintenance venom immunotherapy at 3-month intervals.
    Goldberg A; Confino-Cohen R; Mekori YA
    J Allergy Clin Immunol; 1994 Jun; 93(6):997-1001. PubMed ID: 8006322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.